166 related articles for article (PubMed ID: 33128043)
1. Novel targeted mtLivin nanoparticles treatment for disseminated diffuse large B-cell lymphoma.
Abd-Elrahman I; Nassar T; Khairi N; Perlman R; Benita S; Ben Yehuda D
Oncogene; 2021 Jan; 40(2):334-344. PubMed ID: 33128043
[TBL] [Abstract][Full Text] [Related]
2. [Expression of Apoptosis-related Protein Livin and Caspase-3 in Diffuse Large B Cell Lymphoma and Its Clinical Significance].
Jin L; Sui YX; Chen ZZ; Li YH; Wang LP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1664-1669. PubMed ID: 29262894
[TBL] [Abstract][Full Text] [Related]
3. Subcellular localization determines the delicate balance between the anti- and pro-apoptotic activity of Livin.
Nachmias B; Lazar I; Elmalech M; Abed-El-Rahaman I; Asshab Y; Mandelboim O; Perlman R; Ben-Yehuda D
Apoptosis; 2007 Jul; 12(7):1129-42. PubMed ID: 17294084
[TBL] [Abstract][Full Text] [Related]
4. Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma.
Yang Y; Kelly P; Shaffer AL; Schmitz R; Yoo HM; Liu X; Huang DW; Webster D; Young RM; Nakagawa M; Ceribelli M; Wright GW; Yang Y; Zhao H; Yu X; Xu W; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza L; Staudt LM
Cancer Cell; 2016 Apr; 29(4):494-507. PubMed ID: 27070702
[TBL] [Abstract][Full Text] [Related]
5. tLivin displays flexibility by promoting alternative cell death mechanisms.
Shiloach T; Berens C; Danke C; Waiskopf O; Perlman R; Ben-Yehuda D
PLoS One; 2014; 9(6):e101075. PubMed ID: 24960127
[TBL] [Abstract][Full Text] [Related]
6. The inhibitor of apoptosis protein Livin (ML-IAP) plays a dual role in tumorigenicity.
Abd-Elrahman I; Hershko K; Neuman T; Nachmias B; Perlman R; Ben-Yehuda D
Cancer Res; 2009 Jul; 69(13):5475-80. PubMed ID: 19549891
[TBL] [Abstract][Full Text] [Related]
7. Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma.
Zhou X; Chen N; Xu H; Zhou X; Wang J; Fang X; Zhang Y; Li Y; Yang J; Wang X
J Hematol Oncol; 2020 Jun; 13(1):77. PubMed ID: 32546241
[TBL] [Abstract][Full Text] [Related]
8. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling.
Yang J; Li Y; Zhang Y; Fang X; Chen N; Zhou X; Wang X
J Exp Clin Cancer Res; 2020 Jul; 39(1):142. PubMed ID: 32711549
[TBL] [Abstract][Full Text] [Related]
9. The Inhibitor of Apoptosis Protein Livin Confers Resistance to Fas-Mediated Immune Cytotoxicity in Refractory Lymphoma.
Sugihara E; Hashimoto N; Osuka S; Shimizu T; Ueno S; Okazaki S; Yaguchi T; Kawakami Y; Kosaki K; Sato TA; Okamoto S; Saya H
Cancer Res; 2020 Oct; 80(20):4439-4450. PubMed ID: 32928920
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of the truncated form of Livin reveals a complex interaction with caspase-3.
Liu GH; Wang C; Ding ZY
Int J Oncol; 2013 Jun; 42(6):2037-45. PubMed ID: 23563149
[TBL] [Abstract][Full Text] [Related]
11. Silencing Livin induces apoptotic and autophagic cell death, increasing chemotherapeutic sensitivity to cisplatin of renal carcinoma cells.
Wang Z; Liu S; Ding K; Ding S; Li C; Lu J; Gao D; Zhang T; Bi D
Tumour Biol; 2016 Nov; 37(11):15133-15143. PubMed ID: 27677286
[TBL] [Abstract][Full Text] [Related]
12. Livin, a novel marker in lymphoma type distinction.
Tanhaei AP; Ziaei A; Mazrouei S; Keyhanian K; Salehi M
Ann Diagn Pathol; 2014 Jun; 18(3):157-62. PubMed ID: 24767895
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-26a/cyclin-dependent kinase 5 axis controls proliferation, apoptosis and in vivo tumor growth of diffuse large B-cell lymphoma cell lines.
Farina FM; Inguscio A; Kunderfranco P; Cortesi A; Elia L; Quintavalle M
Cell Death Dis; 2017 Jun; 8(6):e2890. PubMed ID: 28640256
[TBL] [Abstract][Full Text] [Related]
14. Research progress on Livin protein: an inhibitor of apoptosis.
Yan B
Mol Cell Biochem; 2011 Nov; 357(1-2):39-45. PubMed ID: 21617971
[TBL] [Abstract][Full Text] [Related]
15. High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era.
Song MK; Yang DH; Lee GW; Lim SN; Shin S; Pak KJ; Kwon SY; Shim HK; Choi BH; Kim IS; Shin DH; Kim SG; Oh SY
Leuk Res; 2016 Mar; 42():1-6. PubMed ID: 26851438
[TBL] [Abstract][Full Text] [Related]
16. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1.
Li L; Pongtornpipat P; Tiutan T; Kendrick SL; Park S; Persky DO; Rimsza LM; Puvvada SD; Schatz JH
Leukemia; 2015 Aug; 29(8):1702-12. PubMed ID: 25882699
[TBL] [Abstract][Full Text] [Related]
17. NFYB potentiates STK33 activation to promote cisplatin resistance in diffuse large B-cell lymphoma.
Feng L; Xu X; Zhao K
Leuk Res; 2021 Dec; 111():106708. PubMed ID: 34536775
[TBL] [Abstract][Full Text] [Related]
18. Effects of RNA interference-mediated knockdown of livin and survivin using monomethoxypolyethylene glycol-chitosan nanoparticles in MG-63 osteosarcoma cells.
Guan HP; Sun JZ; Feng XL; Chen JS; Chen FJ; Cheng XF; Liu XW; Ni B
Mol Med Rep; 2016 Feb; 13(2):1821-6. PubMed ID: 26708654
[TBL] [Abstract][Full Text] [Related]
19. MLN0905, a small-molecule plk1 inhibitor, induces antitumor responses in human models of diffuse large B-cell lymphoma.
Shi JQ; Lasky K; Shinde V; Stringer B; Qian MG; Liao D; Liu R; Driscoll D; Nestor MT; Amidon BS; Rao Y; Duffey MO; Manfredi MG; Vos TJ; D' Amore N; Hyer ML
Mol Cancer Ther; 2012 Sep; 11(9):2045-53. PubMed ID: 22609854
[TBL] [Abstract][Full Text] [Related]
20. Livin contributes to tumor hypoxia-induced resistance to cytotoxic therapies in glioblastoma multiforme.
Hsieh CH; Lin YJ; Wu CP; Lee HT; Shyu WC; Wang CC
Clin Cancer Res; 2015 Jan; 21(2):460-70. PubMed ID: 25370472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
